514 filings
Page 5 of 26
8-K
hxcio1ll662z
7 Mar 19
ArQule Reports Fourth Quarter and Full Year 2018 Financial Results
7:30am
S-8
6ihqg9ksuh6b dn
29 Nov 18
Registration of securities for employees
4:12pm
S-8
6rkcg73ws79
29 Nov 18
Registration of securities for employees
4:11pm
8-K
fk2gvg6 2v7
31 Oct 18
ArQule Reports Third Quarter 2018 Financial Results
7:30am
CT ORDER
h23g0
27 Aug 18
Confidential treatment order
12:00am
8-K
03qa3g
1 Aug 18
ArQule Reports Second Quarter 2018 Financial Results
7:30am
8-K
plgeuc7x
13 Jul 18
ArQule Announces Commencement of Proposed Public Offering of Common Stock
5:06pm
424B5
nsa9zrd
12 Jul 18
Prospectus supplement for primary offering
11:38am
424B5
h8b928f113kq6424 65q
10 Jul 18
Prospectus supplement for primary offering
5:29pm
EFFECT
lsgxe6mn0
31 May 18
Notice of effectiveness
12:15am
CORRESP
sduof3pz1u pkd
29 May 18
Correspondence with SEC
12:00am
UPLOAD
8hak3f8ngrqf8r 2879
24 May 18
Letter from SEC
12:00am
8-K
s0w6l 8tvuy
10 May 18
Report of Matters Voted Upon by Stockholders
4:30pm
8-K
42m2nij
7 May 18
Arqule Reports First Quarter 2018 Financial Results
7:30am
8-K
0xze wf1p
17 Apr 18
ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World excluding Greater China
12:00am
CT ORDER
2cn0o5o
6 Apr 18
Confidential treatment order
12:00am